Met Life Investment Management, LLC 89bio, Inc. Transaction History
Met Life Investment Management, LLC
- $16.5 Billion
- Q2 2025
A detailed history of Met Life Investment Management, LLC transactions in 89bio, Inc. stock. As of the latest transaction made, Met Life Investment Management, LLC holds 74,661 shares of ETNB stock, worth $674,935. This represents 0.0% of its overall portfolio holdings.
Number of Shares
74,661
Previous 66,035
13.06%
Holding current value
$674,935
Previous $480,000
52.71%
% of portfolio
0.0%
Previous 0.0%
Shares
9 transactions
Others Institutions Holding ETNB
# of Institutions
217Shares Held
160MCall Options Held
415KPut Options Held
689K-
Janus Henderson Group PLC London, X020.5MShares$185 Million0.09% of portfolio
-
Ra Capital Management, L.P. Boston, MA19.9MShares$180 Million3.0% of portfolio
-
Suvretta Capital Management, LLC New York, NY14.3MShares$130 Million4.56% of portfolio
-
Deep Track Capital, LP Greenwich, CT9.32MShares$84.2 Million2.37% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.24MShares$74.5 Million0.0% of portfolio
About 89bio, Inc.
- Ticker ETNB
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 46,484,500
- Market Cap $420M
- Description
- 89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also int...